Literature DB >> 20027650

Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease.

Andrew Ippoliti1, Shane Devlin, Ling Mei, Huiying Yang, Konstantinos A Papadakis, Eric A Vasiliauskas, Dermot P B McGovern, Maria T Abreu, Gil Melmed, Omid Shaye, Pedram Enayati, Gary Chen, Jennifer Choi, Kent Taylor, Carol J Landers, Jerome I Rotter, Stephan R Targan.   

Abstract

BACKGROUND: Mutations in the nucleotide oligomerization domain-2 (NOD2) gene and positive antibodies to microbial antigens have been found to be associated with the Crohn's disease (CD) phenotype, fibrostenosis. The aim of this study was to confirm these relationships in a large cohort of CD patients and to determine the correlation between the presence of NOD2 variants and antibodies to oligomannan, CBir, outer membrane porin-C (OmpC), and I2 in CD patients with fibrostenosis.
METHODS: Sera and DNA from 731 unrelated CD patients were tested for NOD2 variants (SNP 8, 12, and 13) and the antibodies. The results were correlated with CD phenotypes, fibrostenosis, internal penetrating, perianal penetrating, and ulcerative colitis (UC)-like as well as other clinical features.
RESULTS: The presence of NOD2 allelic variants was primarily associated with fibrostenosis, secondarily with small bowel disease and small bowel surgery, and was inversely associated with UC-like disease. This association was present in patients with a fibrostenosis only (Vienna B2) and those with both stricturing and penetrating disease. The presence and level of antibodies to microbial antigens was also associated with the fibrostenosis phenotype. In the 316 patients with fibrostenosis the prevalence of NOD2 variants was significantly correlated with the antibody titer by quartile sum score. Further, when these patients with fibrostenosis were clustered by quartile sum score, the odds ratio for fibrostenosis was significantly higher in the patients with NOD2 variant alleles within each cluster, indicating synergy.
CONCLUSIONS: Defects of innate (NOD2 variants) and adaptive (antibodies to microbial antigens) immunity act synergistically to increase the risk of the fibrostenosis phenotype.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20027650      PMCID: PMC3875376          DOI: 10.1002/ibd.21196

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  17 in total

Review 1.  Clinical relevance of advances in genetics and pharmacogenetics of IBD.

Authors:  Tariq Ahmad; Cyrus Pesi Tamboli; Derek Jewell; Jean-Frédéric Colombel
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

2.  A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.

Authors:  C Gasche; J Scholmerich; J Brynskov; G D'Haens; S B Hanauer; E J Irvine; D P Jewell; D Rachmilewitz; D B Sachar; W J Sandborn; L R Sutherland
Journal:  Inflamm Bowel Dis       Date:  2000-02       Impact factor: 5.325

3.  Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations.

Authors:  Konstantinos A Papadakis; Huiying Yang; Andrew Ippoliti; Ling Mei; Charles O Elson; Robert M Hershberg; Eric A Vasiliauskas; Phillip R Fleshner; Maria T Abreu; Kent Taylor; Carol J Landers; Jerome I Rotter; Stephan R Targan
Journal:  Inflamm Bowel Dis       Date:  2007-05       Impact factor: 5.325

4.  The molecular classification of the clinical manifestations of Crohn's disease.

Authors:  Tariq Ahmad; Alessandro Armuzzi; Mike Bunce; Kim Mulcahy-Hawes; Sara E Marshall; Timothy R Orchard; Jonathan Crawshaw; Oliver Large; Arjuna de Silva; Julia T Cook; Martin Barnardo; Sue Cullen; Ken I Welsh; Derek P Jewell
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

5.  T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans.

Authors:  R Duchmann; E May; M Heike; P Knolle; M Neurath; K H Meyer zum Büschenfelde
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

6.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.

Authors:  Y Ogura; D K Bonen; N Inohara; D L Nicolae; F F Chen; R Ramos; H Britton; T Moran; R Karaliuskas; R H Duerr; J P Achkar; S R Brant; T M Bayless; B S Kirschner; S B Hanauer; G Nuñez; J H Cho
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

7.  Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations.

Authors:  Jing Li; Thomas Moran; Eric Swanson; Christina Julian; Jeremy Harris; Denise K Bonen; Matija Hedl; Dan L Nicolae; Clara Abraham; Judy H Cho
Journal:  Hum Mol Genet       Date:  2004-06-15       Impact factor: 6.150

8.  Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease.

Authors:  William S Mow; Eric A Vasiliauskas; Ying-Chao Lin; Phillip R Fleshner; Konstantinos A Papadakis; Kent D Taylor; Carol J Landers; Maria T Abreu-Martin; Jerome I Rotter; Huiying Yang; Stephan R Targan
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

9.  Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease.

Authors:  Naohiro Inohara; Yasunori Ogura; Ana Fontalba; Olga Gutierrez; Fernando Pons; Javier Crespo; Koichi Fukase; Seiichi Inamura; Shoichi Kusumoto; Masahito Hashimoto; Simon J Foster; Anthony P Moran; Jose L Fernandez-Luna; Gabriel Nuñez
Journal:  J Biol Chem       Date:  2003-01-04       Impact factor: 5.157

10.  Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease.

Authors:  Maria T Abreu; Kent D Taylor; Ying-Chao Lin; Tieu Hang; Joanne Gaiennie; Carol J Landers; Eric A Vasiliauskas; Lori Y Kam; Micha Rojany; Konstantinos A Papadakis; Jerome I Rotter; Stephan R Targan; Huiying Yang
Journal:  Gastroenterology       Date:  2002-09       Impact factor: 22.682

View more
  10 in total

Review 1.  The use of prognostic factors in inflammatory bowel diseases.

Authors:  Thomas Billiet; Marc Ferrante; Gert Van Assche
Journal:  Curr Gastroenterol Rep       Date:  2014-11

Review 2.  Central role of IL-17/Th17 immune responses and the gut microbiota in the pathogenesis of intestinal fibrosis.

Authors:  Shuvra Ray; Carlo De Salvo; Theresa T Pizarro
Journal:  Curr Opin Gastroenterol       Date:  2014-11       Impact factor: 3.287

3.  Meta-analysis of early bowel resection versus initial medical therapy in patient's with ileocolonic Crohn's disease.

Authors:  Éanna J Ryan; Gabriel Orsi; Michael R Boland; Adeel Zafar Syed; Ben Creavin; Michael E Kelly; Kieran Sheahan; Paul C Neary; Dara O Kavanagh; Deirdre McNamara; Des C Winter; James M O'Riordan
Journal:  Int J Colorectal Dis       Date:  2020-01-09       Impact factor: 2.571

Review 4.  Clinical Utility of Biomarkers in IBD.

Authors:  Gerhard Rogler; Luc Biedermann
Journal:  Curr Gastroenterol Rep       Date:  2015-07

5.  Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior.

Authors:  Gary R Lichtenstein; Stephan R Targan; Marla C Dubinsky; Jerome I Rotter; Derren M Barken; Fred Princen; Susan Carroll; Michelle Brown; Jordan Stachelski; Emil Chuang; Carol J Landers; Joanne M Stempak; Sharat Singh; Mark S Silverberg
Journal:  Inflamm Bowel Dis       Date:  2011-03-09       Impact factor: 5.325

Review 6.  Surgery and diagnostic imaging in abdominal Crohn's disease.

Authors:  Fiorenzo Botti; Flavio Caprioli; Diego Pettinari; Alberto Carrara; Andrea Magarotto; Ettore Contessini Avesani
Journal:  J Ultrasound       Date:  2013-10-16

Review 7.  Surgery versus Medical Therapy in Luminal Ileocecal Crohn's Disease.

Authors:  Michele Carvello; Silvio Danese; Antonino Spinelli
Journal:  Clin Colon Rectal Surg       Date:  2022-01-17

8.  Current and future role of biomarkers in Crohn's disease risk assessment and treatment.

Authors:  Cyrus P Tamboli; David B Doman; Amar Patel
Journal:  Clin Exp Gastroenterol       Date:  2011-06-02

Review 9.  Genetic Influences on the Development of Fibrosis in Crohn's Disease.

Authors:  Bram Verstockt; Isabelle Cleynen
Journal:  Front Med (Lausanne)       Date:  2016-05-30

10.  Multidrug resistance 1 gene polymorphisms may determine Crohn's disease behavior in patients from Rio de Janeiro.

Authors:  Ana Teresa P Carvalho; Renata S B Fróes; Barbara C Esberard; Juliana C V C Santos; Davy C M Rapozo; Ana B Grinman; Tatiana A Simão; Pedro Nicolau Neto; Ronir R Luiz; Antonio José V Carneiro; Heitor S P de Souza; Luis Felipe Ribeiro-Pinto
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.